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INTRODUCTION
Graft-versus-leukemia (GVL) effects in the setting of
allogeneic bone marrow transplantation (alloBMT) repre-
sent an immune-mediated response of donor cells to the
antigens of the host or to leukemia-speciﬁc antigens [1,2].
T cells are felt to play a central role in the GVL response,
and the relative roles of CD4+ and CD8+ cells in the induc-
tion and effector phases of GVL have been extensively stud-
ied in murine models [3-5]. In humans, CD4+ and CD8+
alloreactive cells with antileukemic activity can be generated
in vitro [6], and after bone marrow transplantation (BMT),
an increase in CD4+ precursors with antileukemic activity
has been demonstrated [7]. Nimer et al. [8] used CD8+-
depleted marrow transplants in a randomized clinical trial
and showed a signiﬁcantly lower incidence of graft-versus-
host disease (GVHD) without a significant increase in
leukemia relapse compared with T-cell replete grafts. CD4+
cells may therefore play an important role in both the
induction and effector phases of the GVL response in
humans. Cells of CD8+ lineage have also been shown to
have antileukemic effects and may facilitate engraftment
[9,10]. Cytokines including interleukin (IL)-2, IL-10, IL-11,
and IL-12 have been shown to modulate GVHD and GVL
effects [11-13]. Natural killer cells are known to produce
antileukemic responses in vitro and in animal models and
also to promote engraftment [14-16]. Thus, GVL effects
reﬂect complex immune responses involving various cell lin-
eages and cytokines and are biologically related to the
processes underlying GVHD and engraftment.
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ABSTRACT
Although graft-versus-leukemia effects in allogeneic bone marrow transplantation (alloBMT) are well documented,
graft-versus-tumor (GVT) effects are poorly defined. To investigate the latter, we established a murine model of
breast cancer using TS/A, a transforming growth factor (TGF)-1–secreting breast cancer cell line of BALB/c ori-
gin. In the setting of disparate (parent into F1) alloBMT, no appreciable GVT was identified. To assess whether
TGF-1 secreted by the tumor might inhibit the antitumor response, TGF-1 antisense vector was transfected into
the TS/A breast cancer cell line. Mice were inoculated with either TGF-1 antisense transfected or the mock trans-
fected cell line and underwent syngeneic or alloBMT. No evidence of GVT was appreciated for the mock-trans-
fected breast cancer cell line as assessed by an absence of a statistically significant difference in survival between
syngeneic and alloBMT groups. However, there was a highly statistically significant survival difference between
allogeneic versus syngeneic bone marrow transplantation groups inoculated with the TGF-1 antisense-transfected
cell line (P = .00001) as well as when comparing the survival of mice that received alloBMT for TGF-1 antisense-
transfected tumor versus mock-transfected tumor (P = .0008). These data suggest that (1) GVT exists against the
antisense-transfected breast cancer cells in this experimental model and (2) TGF-1 may be involved in suppressing
antitumor responses in the setting of alloBMT for breast cancer.
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Even though GVL is an established clinical phenomenon
correlated with antileukemic responses and reduced rates of
relapse, graft-versus-tumor (GVT) effects are clinically poorly
defined. The presence of tumor-infiltrating lymphocytes
(TILs) that demonstrate autologous tumor recognition and
tumor-speciﬁc cytotoxicity have been observed by a number of
investigators [17-19] in various solid tumors including breast,
ovarian, melanoma, and renal cancer, thereby providing a basis
for the possibility that allogeneic tumor antigen-speciﬁc donor
cell responses might occur in the setting of alloBMT for solid
tumors. Flow cytometric analysis of TILs in breast cancer has
shown a predominance of CD8+ cells [20], and the presence of
peritumoral lymphatic invasion has been correlated with
improved relapse-free survival but not overall survival [21].
These studies suggest the presence of an immune-mediated
antitumor response against solid tumors. To investigate possi-
ble antitumor responses mediated by donor graft cells against
the host solid tumor in the setting of alloBMT, we estab-
lished a murine alloBMT breast cancer model. To deﬁne this
model system, we initially conﬁrmed the presence of GVL
responses by using a hematologic malignancy—a murine
myelomonocytic leukemia cell line. A statistically signiﬁcant
difference in survival between the alloBMT and syngeneic
BMT groups provided evidence for the presence of GVL
effects against the leukemia line in this model system. In con-
trast, no signiﬁcant difference in survival between the alloBMT
and syngeneic BMT groups was noted for 2 breast cancer lines
evaluated, consistent with a lack of appreciable GVT.
This led us to hypothesize that the lack of appreciable
GVT might be due to a negative regulatory cytokine pro-
duced by the cancer cells that suppressed the antitumor
responses against breast cancer. Reports exist in the literature
of solid tumors secreting mediators of immunosuppression.
A factor has been reported to be produced by an esophageal
squamous carcinoma cell line that mediated irreversible sup-
pression of in vitro proliferative responses of lymphoid cells
[22]. Gliomas are known to secrete an immunosuppressive
factor that has been identiﬁed as transforming growth factor
(TGF)-2 [23,24]. Fakhrai et al. [25] reported the eradica-
tion of established rat gliomas by TGF- antisense gene
therapy. Immunizations of animals with genetically modiﬁed
glioma cells in which TGF-2 secretion was inhibited by
antisense transfection resulted in complete responses at the
site of the established gliomas, and in vitro assays showed an
increase in tumor cytotoxicity by lymph node effector cells.
TGF-1 is produced in appreciable amounts by human and
murine breast cancer cells. Both JC and TS/A, the murine
breast cancer cell lines we tested in this model, produced
appreciable amounts of TGF-1. To assess whether the
TGF-1 produced by these tumor lines was suppressing the
antitumor response, we transfected a TGF-1 antisense gene
construct into the cell lines and then tested for evidence of
GVT in our murine model of alloBMT.
MATERIALS AND METHODS
Mice
C57BL/6 (B6, H-2b), (B6xBALB/c) Fl (CB6Fl, H-2bxd)
were bred at the Frederick Cancer Research Center (Fred-
erick, MD). All recipient mice were 10 to 20 weeks of age at
the time of BMT.
Tumor Cell Lines
(Original strain and type of malignancy are shown in
parentheses.) WEHI-3 (BALB/c, myelomonocytic leukemia
cell line), JC (BALB/c, breast cancer), and TS/A (BALB/c,
breast cancer) lines were used for comparing GVT with
GVL and for further deﬁning GVT. JCm120 and TS/A A2
are the cell lines produced by transfecting TGF-1 antisense
gene construct into JC and TS/A tumor cell lines, respec-
tively; TS/A chloramphenicol acetyltransferase (CAT) is the
mock-transfected line used as the control for experiments
designed to evaluate for GVT against TS/A A2. Cell culture
medium for the breast cancer cell lines consisted of RPMI
1640 with 10% fetal calf serum (FCS), sodium pyruvate
(1%), nonessential amino acid (1%), L-glutamine (0.5%),
penicillin (0.5%), and streptomycin (0.5%). For the leukemia
cell line WEHI-3, DMEM was used instead of RPMI 1640.
Generation of Antisense Cell Line
To generate the TGF-1 antisense vector, a DNA frag-
ment containing bases 120 to 1317 of mouse TGF-1
cDNA [26] was ampliﬁed by polymerase chain reaction and
ligated in reverse orientation in the NcoI/BamHI sites of the
MFG vector [27]. The MFG vector is a simpliﬁed retroviral
vector without a dominant selectable marker gene. The vec-
tor was derived from the moloney murine leukemia virus
in which the polymerase (pol) and envelope (env) gene
sequences were deleted to render it replication-defective.
The MFG retroviral vector containing an internal ribosome
entry site (IRES) [28] of the encephalomyocarditis virus was
provided by Dr. P. Robbins (University of Pittsburgh School
of Medicine, Pittsburgh, PA). A neomycin resistance gene,
containing an IRES to form a fusion RNA with the anti-
sense TGF-1 RNA, was then subcloned into the BamHI
site for a stable selection of infected cells. To generate a high
titer, 10 µg plasmid was cotransfected with 2.5 µg
pCMV–VSV-G into an ABOSC packaging cell. (BOSC 23
cells are derived from the Ad-5 transformed human embry-
onic kidney 293 cell line [29]. ABOSC cells are amphotropic
BOSC cells containing an amphotropic envelope.) MFG-
CAT was used as a control [30]. When the cells reached
80% confluence, the medium was replaced, and the cells
were grown for 24 hours. Retroviral supernatant was then
harvested and applied directly to the tumor cells. G418 cells
were selected and characterized by Northern blot analysis
and enzyme-linked immunosorbent assay (ELISA). Frozen
samples were used after suspending them in culture medium
for a few days before the experiments.
BMT Model to Evaluate Antitumor Responses
Recipient mice were exposed to 1000 cGy of radiation
4 to 6 hours before BMT. Bone marrow cells were aspirated
from the femurs and tibias of donor mice. Then, 5  106
unmanipulated bone marrow cells along with varying
numbers of spleen cells were injected into the tail vein of
recipient mice (5 mice/group). The purpose of these initial
experiments was to determine the minimal number of
spleen cells that produced clinically evident but minimal
GVHD, as evidenced by significant weight loss without
mortality. The number of spleen cells subsequently used in
all the transplant experiments was 0.5  106 (data not
shown). The tumor cell number was ascertained by injecting
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varying numbers of tumor cells intraperitoneally and moni-
toring for survival. We selected the tumor cell dose that was
lethal at 4 to 5 weeks as the number of tumor cells to be used
for subsequent experiments. Therefore, 104 cells of the
WEHI-3 leukemia cell line, 105 cells of JC, or 105 cells of
the TS/A breast cancer cell line were injected per mouse.
Tumor cells were injected intraperitoneally at the same time
that marrow was injected intravenously for the BMT. In
these experiments, we compared 2 BMT groups: B6 into
CB6F1 (MHC disparity, alloBMT) and CB6F1 into CB6F1
(syngeneic BMT). There were 10 mice per group for each
of the experiments, and each experiment was repeated at
least twice. Mice were monitored for survival for up to 60
days after transplantation and were examined to confirm
tumor involvement of the spleen, liver, lung, peritoneum,
and original organs. Mice that died before day 10 after
transplantation showed no gross evidence of tumor.
Statistical Analysis
Survival data were analyzed using the likelihood ratio
test of the Cox proportional hazards model with exact likeli-
hood for tied survival times.
ELISA Assay for TGF-1 Secretion by the Tumor Cells
The 1.3  106 tumor cells were suspended in a 10-cm
culture dish containing 8 mL RPMI 1640 without FCS.
The supernatant was collected 24 hours later. The concen-
tration of TGF-1 was assayed using a human TGF-1
ELISA kit (R&D Systems, Minneapolis, MN). The proce-
dure complied with the reference manual in the kit, and the
results are reported in nanograms per milliliter.
Northern Blot Analysis for TGF-1 mRNA
Total RNA was isolated with guanidinium isothio-
cyanate-phenol chloroform. Total RNA (10 µg) was elec-
trophoresed on a 10% agarose gel containing 0.66 mol/L
formaldehyde, transferred to a Zeta-Probe blotting mem-
brane (Bio-Rad, Hercules, CA), and cross-linked with a UV
Stratalinker (Stratagene, La Jolla, CA). Blots were hybridized
with cDNA probes for neomycin and TGF-1 cDNAs.
RESULTS
GVT Versus GVL
To deﬁne the model system as one with GVL activity,
we ﬁrst evaluated for the presence of allogeneic effects using
the murine leukemia cell line WEHI-3, known to be sus-
ceptible to GVL activity. For the mice inoculated with
WEHI-3, a statistically signiﬁcant difference in survival was
observed between the allogeneic group and the syngeneic
controls in favor of the alloBMT group (Figure 1, P =
.0001), conﬁrming the presence of an active GVL effect in
this model that lacked lethal GVHD. This GVL effect was
dependent on an allogeneic disparity of donor marrow and
tumor because no significant difference in survival was
noted between the syngeneic BMT group and the group of
mice that received BALB/c bone marrow (H-2d bone mar-
row with the tumor also being H-2d, data not shown). Hav-
ing established the model, we investigated whether a GVT
effect against the murine breast cancer cell lines JC and
TS/A might exist. There was no statistically signiﬁcant dif-
ference in survival observed between the allogeneic and syn-
geneic BMT groups for the mice inoculated with either JC
or TS/A cancer cell lines (Figure 2, JC data not shown). No
deaths were observed for the mice that underwent alloBMT
or syngeneic BMT without tumor inoculation. These obser-
vations led us to conclude that (1) antileukemia effects can
be detected using this model system, as evidenced by the
presence of GVL against WEHI-3, and (2) there is a lack of
appreciable GVT against the murine breast cancer cell lines
used in this model system.
Role of TGF-1 in Suppressing GVT
Expression of TGF-1 mRNA and Protein by the Tumor Cells
Using Northern blot analysis and ELISA assay, we
determined the presence of TGF-1 mRNA and protein
Figure 1. Survival of mice after allogeneic bone marrow transplanta-
tion (alloBMT) versus syngeneic bone marrow transplantation using
the murine myelomonocytic cell line WEHI-3. CB6F1 mice were irra-
diated (1000 cGy), and 5  106 unmanipulated bone marrow cells from
either B6 (allogeneic, ) or CB6F1 (syngeneic, ) donor mice along
with 0.5  106corresponding spleen cells were injected intravenously at
the same time that WEHI-3 leukemia cells were injected intraperi-
toneally. There was a significant difference in survival between the
2 groups in favor of alloBMT (P = .0001)
Figure 2. Survival curves for mice after allogeneic bone marrow trans-
plantation (alloBMT) versus syngeneic bone marrow transplantation
(BMT) for the murine breast cancer cell line TSA. , alloBMT group;
, syngeneic BMT group. There was no appreciable difference in sur-
vival (P = .18) between the 2 groups.
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produced by JC and TS/A cell lines. We observed that both
JC and TS/A constitutively express TGF-1 mRNA and
secrete appreciable amounts of TGF-1. We then pro-
ceeded to transfect a TGF-1 antisense construct into the
cell lines, producing JCm120 and TS/A A2, respectively,
with an associated marked decrease in the level of TGF-1
secretion. These cells express low levels of TGF-2, and the
TGF-1 antisense did not have any effect on the level of
secretion of TGF-2 (data not shown). The growth rate of
JC and TS/A cells transfected with the TGF-1 antisense
virus was not different from that of MFG-CAT expressing
controls in vitro (data not shown). Figure 3A and B show
the level of TGF-1 mRNA and protein expression, respec-
tively, by the parent breast cancer lines compared with the
TGF-1 antisense-transfected tumor lines. JC and TS/A
cells infected with either MFG-antisense TGF-1-IRES-
neo virus or the MFG-CAT-IRES-neo were selected in the
presence of G418. Even after 10 to 20 passages, TGF-1
secretion was markedly suppressed in the TGF-1 anti-
sense-containing cells.
TS/A CAT Versus TS/A A2
We hypothesized that the lack of appreciable GVT
against the breast cancer cells might be due to the suppres-
sion of antitumor responses by TGF-1 produced by the
tumor cells. After transfecting the TGF-1 antisense vector
into the TS/A cells and significantly reducing the level of
TGF-1 secretion, we compared the survival between the
allogeneic and syngeneic groups for the TS/A A2 cell line.
The mock-transfected tumor cell line TS/A CAT was used
as a negative control for these experiments. No evidence of
GVT was observed for the mock-transfected line (TS/A
CAT) because there was no difference in survival between
the alloBMT group and the syngeneic BMT group (Figure 4,
P = .087). However, we observed a statistically significant
difference in survival between the 2 groups for the TGF-1
antisense-transfected tumor cell line, TS/A A2 (Figure 4,
P = .00001). When comparing the survival of mice that
underwent alloBMT for mock-transfected versus TGF-1
antisense-transfected tumor, a highly statistically signifi-
cant difference in survival was observed in favor of the
TGF-1 antisense-transfected line (P = .0008). Similar
results were noted for the JC tumor line with a statistically
significant difference in survival in favor of the TGF-1
antisense-transfected JCm120 compared to JC, the parent
breast cancer line (data not shown). Based on these experi-
mental data, we conclude that (1) GVT against breast can-
cer exists and (2) TGF-1 produced by the tumor cells plays
Figure 3. Expression of transforming growth factor (TGF)-1 mRNA
and protein by the tumor cells. A, Northern blot analysis of TGF-1
mRNA. Total RNA was isolated from the tumor cell lines and analyzed
by Northern blot analysis using 32P-labeled TGF-1 and neomycin
probes. (i) JC (parent cell line, lane 1) and JCm120 (TGF-1 antisense-
transfected cell line, lane 2); (ii) TSA CAT (mock-transfected cell line,
lane 1) and TSA A2 (TGF-1 antisense-transfected cell line, lane 2).
B, Enzyme-linked immunosorbent assay (ELISA) to determine the level
of TGF-1 by the tumor cells: 1.3  106 tumor cells were suspended in
a 10-cm culture dish containing 8 mL RPMI 1640 without fetal calf
serum. The supernatant was collected 24 hours later. The concentration
of TGF-1 was assayed using a human TGF-1 ELISA kit (R&D Sys-
tems, Minneapolis, MN). The procedure complied with the reference
manual in the kit, and the results are reported in nanograms per milli-
liter. (i) JC (parent cell line, lane 1) and JCm120 (TGF-1 antisense-
transfected cell line, lane 2); (ii) TSA CAT (mock-transfected cell line,
lane 1) and TSA A2 (TGF-1 antisense-transfected cell line, lane 2).
Figure 4. Survival of mice after allogeneic bone marrow transplanta-
tion (alloBMT) versus syngeneic bone marrow transplantation (BMT) for
TS/A CAT (the mock-transfected cell line) and TS/A A2 (the TGF-1
antisense-transfected murine breast cancer cell line). , alloBMT
group for TS/A CAT; , TS/A A2; , syngeneic BMT group for
TS/A CAT; , TS/A A2. As shown, there was no signiﬁcant difference
in survival between the 2 groups (P = .087) for the TS/A CAT cells,
whereas there was a significant difference in survival in favor of
alloBMT (P = .00001) for the TS/A A2 cell line. A statistically signiﬁ-
cant difference in survival was also noted when comparing the survival
of mice that received alloBMT for TS/A A2 versus TS/A CAT, in
favor of TS/A A2 (P = .0008). Deaths occurring before day 10 after
BMT are not shown because no evidence of gross tumor was found,
and these deaths were felt to be non-tumor related.
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a role in suppressing the antitumor response against breast
cancer in this murine allogeneic BMT model.
DISCUSSION
Despite advances in the field of oncology, metastatic
breast cancer remains an essentially incurable disease, with
5-year progression-free survivals in the range of 15% to
20% after autologous BMT [31]. Allogeneic BMT, in spite
of higher risk of toxicity, presents the possibility of longer
progression-free survivals and possible cures attributed to
potential GVT effects. Such effects have been well docu-
mented against hematologic malignancies, but little evi-
dence exists for GVT against solid tumors. Ueno et al. [32]
reported the results of a clinical trial involving 10 patients
who underwent alloBMT for metastatic breast cancer, in
which 2 of the 10 patients had regression of liver lesions in
association with evidence of skin GVHD after the with-
drawal of immunosuppressive treatment. Reports also exist
in the literature of cytotoxic T cells recognizing and lysing
breast cancer cells in vitro and in vivo [33]. Despite these
ﬁndings that suggest a possible basis for GVT in alloBMT
for the treatment of breast cancer, GVT effects against
breast cancer in a clinical setting remain more a matter of
potential than demonstration.
To further study antitumor responses against breast cancer
in vivo, we established a preclinical alloBMT model. In this
model, no evidence of GVT against breast cancer was found,
even though signiﬁcant GVL effects were noted against the
murine leukemia cell line. This led to the hypothesis that the
breast cancer cells may be producing a negative regulatory
cytokine that suppresses the antitumor response in the setting
of alloBMT and that such a cytokine might be TGF-.
Walker and Dearing [34] reported that the production of
TGF- increases with advancing stages of breast cancer. Even
though TGF- is the most potent physiological inhibitor of
cell cycle progression of normal mammary epithelial cells, the
increased production of TGF- by advanced breast cancer
cells suggests that TGF- may provide an advantage for
tumor progression [35-37]. Park et al. [38] have demonstrated
that inhibiting the production of TGF- by a murine mam-
mary tumor line reduces its tumorigenicity. It has been
demonstrated that advanced breast cancer cells acquire resis-
tance to the effects of TGF- by inactivation of either 1 of the
2 TGF- receptors [39]. Therefore TGF-, a known
immunosuppressant, is produced by the cancer cells and may
promote tumor progression by suppressing antitumor
immune responses without affecting the tumor cells. There-
fore, to investigate the role of TGF- in suppression of these
antitumor responses, we transfected the tumor cells with a
TGF-1 antisense construct, appreciably reducing the level of
TGF-1 secretion compared with the level at baseline. Upon
using the TGF-1 antisense-transfected cell line in our model
system, we detected a signiﬁcant difference in survival between
the allogeneic versus syngeneic BMT groups for the anti-
sense-transfected cell line as well as a signiﬁcant difference in
survival between the alloBMT groups for the antisense-trans-
fected versus the mock-transfected cell lines, indicating the
presence of GVT against the antisense-transfected cell line.
Thus, in our model system, the transfection of the antisense
construct and the subsequent decrease in the level of TGF-1
secretion unmasked the GVT effect resulting in prolonged
survival of the mice. This result led us to conclude that
(1) breast cancer cells are susceptible to antitumor immune
responses (GVT), and (2) TGF-1 is involved in suppressing
these responses in the setting of alloBMT in our model.
We should emphasize that even though the suppression
of TGF-1 secretion by the breast cancer line unmasked the
GVT effect, resulting in a significant increase in survival,
“‘cures” did not result. This ﬁnding indicates that there are
other factors that contribute to the modulation of the GVT
response and tumor growth. The mechanism of GVT in
this model and its modulation by TGF-1 is the subject of
ongoing investigation.
These observations may have clinical and therapeutic
implications because they provide further rationale for
the development of alloBMT as a treatment modality for
metastatic breast cancer and of treatment strategies aimed at
suppressing the production of TGF-1 by breast cancer cells.
These considerations raise possibilities of T cell–adoptive
immunotherapy either by using T cells genetically manipulated
ex vivo to be resistant to the immunosuppressive effects of
TGF-1 or by generating a T-cell response ex vivo to the anti-
sense-transfected tumor cells and then transfusing these cells in
an effort to bypass the local immunosuppressive effects on gen-
eration of cytotoxic T lymphocytes with speciﬁcity for breast
cancer cells.
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